Although the overexpression of MET is rare (1-4%), it provides an underlying target for HCC treatment [25, 95] There are two small molecular inhibitors being evaluated in HCC treatment, cabozantinib and tivantinib. This evidence concerns the gene MET and hepatocellular carcinoma.